Kemin Develops Phenolic Complex for Mind and Body Support
27 Apr 2015 --- Kemin has announced the launch in Europe of Neumentix Phenolic Complex K110-42, a proprietary phenolic complex sourced from patent-pending, non-GMO lines of Kemin Industries’ own purpose-grown spearmint for use in food supplements.
Backed by two human clinical trials, Neumentix has been shown to provide natural support for an important component of cognitive performance - working memory - in addition to other unique related benefits.
Neumentix is derived from patent-pending, non-GMO lines of spearmint developed by Kemin plant scientists using traditional plant-breeding methods and grown in the USA on family farms that have been passed down from generation to generation. “There is a high demand for innovative cognitive health ingredients, and the solid clinical results open up great opportunities for customers who use Neumentix in their finished products”, said Pedro Vieira, vice president of sales & marketing for the human nutrition and health division of Kemin in Europe and South America.
Cognitive health and performance were assessed in the study “Effects of a Proprietary Spearmint Extract on Cognitive Function and Tolerance Parameters in Men and Women with Age-Associated Memory Impairment”. Several validated clinical questionnaires were used including the Cognitive Drug Research (CDR) battery of tests, the Profile of Mood States (POMS) and the Leeds Sleep Evaluation Questionnaire (LSEQ). In this 90 day randomized, double-blind, placebo-controlled study, adults who took Neumentix showed significantly better quality of working memory - a type of memory critical to a wide range of cognitive tasks including multi-tasking and complex thought - compared to those who took placebo.
In addition, people taking Neumentix also reported that they got to sleep easier and faster at night. Working memory is highly affected by the aging process and other factors such as stress or lack of sleep. This data suggests Neumentix helps to improve cognitive performance in adults and confirms the findings observed in the pilot open-label human clinical trial and the in-vivo study conducted at the beginning of product development.
